{"id":"proactive-tdm-based-dosing-of-ixekizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Candida infections"},{"rate":null,"effect":"Inflammatory bowel disease (exacerbation or new onset)"}]},"_chembl":{"chemblId":"CHEMBL324631","moleculeType":"Small molecule","molecularWeight":"643.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ixekizumab is a monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking IL-17A, the drug suppresses Th17 cell-mediated inflammation. This entry describes a therapeutic drug management (TDM) approach using proactive therapeutic drug monitoring to optimize ixekizumab dosing based on serum concentrations and clinical response.","oneSentence":"Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:38.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis (plaque psoriasis)"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":"Psoriasis Vulgaris","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taltz"],"phase":"marketed","status":"active","brandName":"Proactive TDM-based dosing of ixekizumab","genericName":"Proactive TDM-based dosing of ixekizumab","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ixekizumab is an IL-17A inhibitor that blocks interleukin-17A signaling to reduce inflammatory responses in autoimmune conditions. Used for Psoriasis (plaque psoriasis), Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}